Zenas Yiu

Jul 8, 2024 | acrjournals.onlinelibrary.wiley.com | Sizheng Zhao |Kimme Hyrich |Zenas Yiu |Anne Barton

INTRODUCTION Inhibitors of the interleukin 13 (IL-13) pathway, such as dupilumab (dual interleukin 4 [IL-4]/IL-13 inhibitor), tralokinumab, and lebrikizumab (pure IL-13 inhibitors), were developed to treat atopic diseases including atopic dermatitis, chronic rhinosinusitis, and asthma.1-4 Musculoskeletal adverse events resembling seronegative spondyloarthritis have been reported after dupilumab initiation, but evidence is limited to case series and spontaneous pharmacovigilance with uncertain...

Aug 22, 2023 | dialnet.unirioja.es | Sizheng Zhao |Zenas Yiu |Anne Barton |John Bowes

Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization StudyAutores: Sizheng Steven Zhao, Zenas Z.N. Yiu, Anne Barton, John BowesLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 159, Nº. 3, 2023, págs. 275-280Idioma: inglésEnlacesTexto completoResumenImportance Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties.